About US
Contact us
-
Women with pregnancy losses are at risk of cardiovascular diseaseResearch from the UK’s University of Cambridge and the University of North Carolina in the US has revealed women have anincreased risk of cardiovascular disease from pregnancy losses and hav2018/12/3
-
Innovent and Hutchison to test sintilimab and fruquintinib combinationInnovent Biologics (Suzhou) has entered into a global collaboration agreement to evaluate the safety of its sintilimab in combination with Hutchison MediPharma’s fruquintinib to treat patients with ad2018/12/3
-
Roche subsidiary Genentech to acquire Jecure TherapeuticsSwiss firm Roche Group’s affiliate Genentech has agreed to acquire US biotechnology company Jecure Therapeutics to strengthen its position in the treatment of liver diseases. Based in San Diego, Cali2018/11/30
-
X4 Pharmaceuticals signs agreement to merge with Arsanis subsidiaryX4 Pharmaceuticals has signed a definitive agreement to merge with a wholly owned subsidiary of Arsanis in an all-stock transaction. The merger is set to result in a combined company operating under2018/11/30
-
Sun Pharmaceutical agrees to acquire Japan’s Pola PharmaIndia-based drugmaker Sun Pharmaceutical Industries has signed a definitive agreement to acquire Pola Pharma, a Japan-based pharma firm involved in theresearch, development, manufacture, and sale of b2018/11/29
-
EC approves Sandoz’s biosimilar Ziextenzo for febrile neutropeniaNovartis unitSandozhas received marketing authorisation from the European Commission (EC) for biosimilar Ziextenzo (pegfilgrastim). Ziextenzo is intended to cut down the duration of neutropenia and i2018/11/29
-
FDA grants ODD for AstraZeneca’s Fasenra to treat EGPAThe US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for AstraZeneca’s Fasenra (benralizumab) to treat eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoi2018/11/28
-
Nuformix expands licensing agreement with NSB for NXP001Nuformix has expanded its licensing agreement with its Chinese licensing partner Newsummit Biopharma (NSB) for NXP001, which is being developed for cancer supportive care. In order to further validat2018/11/28
-
EC approves Mundipharma’s Pelmeg to treat febrile neutropeniaThe Mundipharma network of independent associated companies has received European Commission (EC) approval for the use of Pelmeg (pegfilgrastim) for treatment of febrile neutropenia in adult cancer pa2018/11/27
-
Fluidic Analytics gains funding for lab-tools products launchUK-based Fluidic Analytics has raised $31m in the latest round of financing led by European venture capital fund Draper Esprit. Other major investors include IQ Capital, Delin Ventures, the Business2018/11/27